Zoom Analysts Turn Active as Oppenheimer Upgrades and Insiders Sell

ZM fell 0.7% over the past week to $97.46, a soft performance against a peer group that averaged gains of more than 4%, with INTA up nearly 13% and DOCU advancing 11% in the same period.

The busiest desk this week was the analyst community. Oppenheimer upgraded Zoom to Outperform with a $130 price target on Wednesday, the most notable single move because it shifts an analyst off the sidelines ahead of the November 23 earnings date. The broader tone stayed constructive: RBC Capital and Rosenblatt each reiterated their $130 Buy-equivalent ratings, and BTIG held at $125. UBS was the lone dissenter, trimming its target from $115 to $112 while staying at Neutral. Cantor Fitzgerald anchored the lower end of the range at $104. Across 17 buys and 10 holds, the mean target is $118.58, roughly 22% above current levels, though the gap between the most cautious and most optimistic views is wide enough to suggest the Street is genuinely divided on how AI monetization plays out.

The bull case rests on enterprise momentum: revenue growing 4.9% to $1.28 billion last quarter, enterprise now 62% of the total and growing at 7.8%, and AI features appearing in nine of the top ten Zoom Contact Center deals. The bear case is more structural. Non-GAAP gross margin slipped from 79.9% to 79.1% as AI-related costs rose. Online revenue growth decelerated to 1% and management cut its full-year online outlook to flat, citing weakness at the top of the funnel. At a P/E of 15.5 and EV/EBITDA of 9.1, valuation is not stretched by software standards, but neither does it leave room for further execution misses against intensifying competition from Microsoft and Cisco.

Options positioning has become the most bullish data point in the snapshot. The put/call ratio is at 0.44, its lowest level of the past year and nearly 1.7 standard deviations below its 20-day average of 0.47. That reading has extended the gradual drift lower noted in last week's note, where the PCR was 0.45. Calls now dominate the options market by a wider margin than at any point in the past twelve months. The 52-week high PCR of 0.80 is a reminder of how differently the market was positioned at the other extreme. Short interest is 2.5% of free float, up about 6% over the week after a period of covering, though the absolute level remains low. Borrow conditions are extremely loose, with availability at roughly 6,600%, meaning shares available to lend vastly outnumber those currently borrowed. Cost to borrow has fallen sharply, down 34% on the week to 0.35%, its lowest rate in a month.

Insider activity is worth noting but requires context. The 90-day net is negative: insiders have sold a net $10.4 million over that window. Most of those sales, including those from the CFO and President of Engineering, were executed under pre-arranged 10b5-1 plans and carry limited signal value. CEO Eric Yuan exercised options on 46,823 shares on October 9, though the associated tax-withholding disposal of 23,824 shares at $85.68 means the net economic exposure from that transaction was a fraction of the gross figure. Founder Yuan still holds 7.1% of shares outstanding. Wikimedia data adds a footnote: retail attention to Zoom's Wikipedia page is running more than two standard deviations above its own 90-day history, its highest reading in the current dataset, though this is an attention signal rather than a financial indicator.

The November 23 print is the clearest near-term reference point. The last quarterly result, in August, produced a one-day decline of 10.5% and a five-day move of negative 9.5%, the sharpest post-earnings reaction in the recent history. What the options market is telling you, with PCRs at a year-low, is that the memory of that selloff has not translated into hedging demand this time around.